FILE PHOTO: People enter a building of biotechnology firm BeiGene Ltd at the Suzhou Industrial Park in Suzhou, Jiangsu province, China November 22, 2019. Picture taken November 22, 2019. REUTERS/Stringer
(Reuters) – BeiGene Ltd said on Tuesday its cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.
The therapy, tislelizumab, when administered in combination with chemotherapy helped reduce the risk of cancer progression in patients with squamous non-small cell lung cancer.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
Reuters source:
